Frost & Sullivan Applauds GBDbio's Disruptive TB REaD™ POC Diagnostics Specifically for Developing Countries

Description

Frost & Sullivan Applauds GBDbio'sFrost & Sullivan Applauds GBDbio's Disruptive TB REaD™ POC Diagnostics Specifically for Developing Countries PR Newswire MOUNTAIN VIEW, California, Feb. 26, 2014 -- By creating a product that precisely mirrors the needs and requirements of the market, GBDbio has been successful in gaining buy-ins from the key players to ensure a running start Frost & Sullivan is pleased to present GBDbio with the 2014 Visionary Innovation Leadership Award for Improving Healthcare Access Globally for its revolutionary TB REaD™ point-of-care (POC) diagnostic for tuberculosis (TB). This groundbreaking product is being developed to offer cutting-edge medical efficacy and quality, while remaining accessible to low-resource communities by being extremely affordable and portable. GBDbio has uniquely paired the technology with a robust business model based on exceptionally low production costs. The result is a double-bottom-line solution that is primed to find rapid uptake in its target markets. In GBDbio's target markets, sporadic electricity, high temperatures, water shortages, and a poorly trained workforce constrain healthcare innovation and delivery. Regions such as Southeast Asia, Sub-Saharan Africa, and the Middle East continue to report high numbers of TB deaths, despite it being a highly treatable disease.

Informations

• Publié par: frost-sullivan
• Publié le: 26 février 2014
• Nombre de lectures: 0
• Langue: English

Extrait

Frost & Sullivan Applauds GBDbio's Disruptive TB REaD™ POC Diagnostics Specifically for Developing Countries

PR Newswire

MOUNTAIN VIEW, California, Feb. 26, 2014

-- By creating a product that precisely mirrors the needs and requirements of the market, GBDbio has been successful in gaining buy-ins from the key players to ensure a running start